Aquestive secures $75M funding from RTW for Anaphylm launch, contingent on FDA approval

Aquestive Therapeutics, Inc.

$75M purchase price from RTW, subject to FDA approval of Anaphylm and refinancing of existing 13.5% senior notes.
Revenue share payments of 7.5%-1.0% of US net sales (9.5% if low sales) capped at $187.5M by 2035 or $225M thereafter.
Funding supports commercial launch; CEO says capital through 2027; Cantor Fitzgerald advised Aquestive.
RTW Managing Partner Roderick Wong: 'investment reflects belief in Anaphylm's commercial prospects.'

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.